P0617 - Reasons for Treatment Discontinuation in Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation

Sunday, October 27, 2024

3:30 PM – 7:00 PM ET

Location: Exhibit Hall E

Has Audio

Presenting Author(s)

ES

Eric Shah, MD, MBA, FACG

University of Michigan
Ann Arbor, MI

Award: Presidential Poster Award

Eric Shah, MD, MBA, FACG¹, Brian E. Lacy, MD, PhD, FACG², William D. Chey, MD, FACG¹, Evan Mavrommatis, PhD³, Moming Li, PhD⁴, Kayla Reid, PhD⁵, Darren M.. Brenner, MD⁶
¹University of Michigan, Ann Arbor, MI; ²Mayo Clinic, Jacksonville, FL; ³AbbVie, Inc, North Chicago, IL; ⁴AbbVie, Inc., North Chicago, IL; ⁵Ironwood Pharmaceuticals, Inc., Boston, MA; ⁶Northwestern University, Chicago, IL

Introduction: Irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) are characterized by chronic abdominal and bowel symptoms. Prescription and over-the-counter (OTC) medications are used to treat symptoms of IBS-C and CIC; however, treatment discontinuation is common. This survey-based study was performed to assess reasons for treatment discontinuation among patients with IBS-C or CIC.

Methods: Self-reported data from adults in the US were collected through two online surveys between August 2020 and December 2021. Participants were included in this analysis if they selected IBS or chronic constipation in the comorbid conditions checklist and reported a physician diagnosis of IBS-C or CIC. Treatment discontinuation rates and reasons for discontinuing treatment were evaluated among participants who reported taking the most frequently used medications for IBS-C/CIC symptoms (prescribed linaclotide or lubiprostone, or OTC polyethylene glycol 3350 [PEG]).

Results: Of 29,359 survey participants, 1,575 (5.4%) were included in the physician-diagnosed IBS-C/CIC cohort. The majority of participants were 18–44 years of age (60.6%), female (68.1%) and White (81.4%). Within the past 12 months, 45.5% reported taking prescription medication and 67.7% reported taking OTC medication for IBS-C/CIC symptoms (Table). Discontinuation rates of those who reported using linaclotide (n = 297), lubiprostone (n = 160) or PEG (n = 676) were 37.7%, 47.5% and 45.4%, respectively. ‘Inadequate effect on bowel movement-related symptoms’ was the most frequent reason for discontinuation of linaclotide (32.1%), lubiprostone (35.5%) and PEG (33.2%); followed by ‘side effects’ for linaclotide (24.1%), ‘worked okay for a while but then stopped working’ for lubiprostone (28.9%) and ‘inadequate effect on abdominal symptoms’ for PEG (22.8%; Figure).

Discussion: Inadequate bowel and abdominal symptom improvement, and side effects, were among the most common reasons for discontinuation of linaclotide, lubiprostone and PEG treatment by patients with IBS-C or CIC.

Figure: Reasons for discontinuing treatment for IBS-C/CIC symptoms.

Participants’ self-reported reasons for discontinuing medication taken for bowel movement-related symptoms and/or abdominal symptoms (reasons reported by ≥ 15% of participants are shown).
CIC, chronic idiopathic constipation; HCP, healthcare provider; IBS-C, irritable bowel syndrome with constipation; PEG, polyethylene glycol 3350.

Note: The table for this abstract can be viewed in the ePoster Gallery section of the ACG 2024 ePoster Site or in The American Journal of Gastroenterology's abstract supplement issue, both of which will be available starting October 27, 2024.

Disclosures:

Eric Shah: Ardelyx – Consultant. Ironwood Pharmaceuticals – Consultant. Mahana Therapeutics – Consultant. Mylan – Consultant. Phathom – Consultant. Salix Pharmaceuticals – Consultant. Sanofi – Consultant. Takeda – Consultant.

Brian Lacy: AbbVie – Consultant. Ardelyx – Consultant. Gemelli Biotech – Consultant. Ironwood Pharmaceuticals – Consultant. Salix Pharmaceuticals – Consultant. Takeda – Consultant.

William Chey: AbbVie – Consultant. Ardelyx – Consultant. Atmo BioSciences – Consultant. Comvita – Consultant. Corprata – Stock Options. Dieta Health – Stock Options. FoodMarble Digestive Health – Consultant, Stock Options. Ironwood Pharmaceuticals – Consultant. Modify Health – Stock Options. Nestlé S.A. – Consultant. Phathom Pharmaceuticals – Consultant. Redhill Biopharma – Consultant. Salix Pharmaceuticals – Consultant. Takeda – Consultant. Vibrant Gastro – Consultant.

Evan Mavrommatis: AbbVie – Employee.

Moming Li: AbbVie – Employee, Stock-publicly held company(excluding mutual/index funds).

Kayla Reid: Ironwood Pharmaceuticals – Employee.

Darren Brenner: AbbVie – Consultant, Speaker. Anji Pharmaceuticals – Consultant. Ardelyx – Advisor or Review Panel Member, Consultant, Speaker. Bayer – Consultant. Blueprint Medicines – Advisor or Review Panel Member. CinPhloro – Advisor or Review Panel Member, Consultant. Dr. Reddy's Laboratories – Consultant. Entrinsic Bioscience – Consultant. Gemelli Biotech – Advisor or Review Panel Member, Consultant. Ironwood Pharmaceuticals – Advisor or Review Panel Member, Consultant, Speaker. Laborie – Advisor or Review Panel Member. Mahana Therapeutics – Advisor or Review Panel Member, Consultant. Owlstone Medical – Advisor or Review Panel Member, Consultant, Stock Options. Salix Pharmaceuticals – Advisor or Review Panel Member, Consultant, Speaker. Vibrant Gastro – Advisor or Review Panel Member, Consultant.

Eric Shah, MD, MBA, FACG¹, Brian E. Lacy, MD, PhD, FACG², William D. Chey, MD, FACG¹, Evan Mavrommatis, PhD³, Moming Li, PhD⁴, Kayla Reid, PhD⁵, Darren M.. Brenner, MD⁶. P0617 - Reasons for Treatment Discontinuation in Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.